Investment boosts SpheriTech’s growth
Don explained: “The investment has enabled me to strengthen the team at SpheriTech but also allows me to apply for government funding, such as through loans or research grants. For a company like ours to get off the ground, it’s absolutely essential to secure government finance.”
Don added: “The investment has allowed improvements including the redesign of the company’s website and will play a key part in financing the development of SpheriTech’s intellectual property – for example by allowing applications for new patents to be pursued more quickly. Patent life is 20 years, so every year you take to commercialise a patent means a year’s less revenue.”
SpheriTech currently holds a portfolio of intellectual property covering a diverse range of technologies including peptide synthesis, DNA synthesis, biocatalysis and cell culture. As part of its work the company offers laboratory-based contract research and development, and provides custom synthesis of peptides and contract purification of any molecule, large or small.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.